Adjuvant Strontium90 brachytherapy following excision of conjunctival melanoma
Krause L.1, Bechrakis N. E.1, Wachtlin J.1, Kreusel K. M.3, Höcht S.2, Foerster M. H.1
1Augenklinik und 2Strahlenklinik, Universitäts-Klinkum Benjamin Franklin, FU Berlin
3Augenklinik Marzahn, Berlin
Purpose: Complete excision of conjunctival melanoma is the therapy of choice. Because of high local recurrence rates adjuvant local chemotherapy with mitomycin or irradiation is recommended. External beam irradiation, strontium or ruthenium plaque brachytherapy are radiotherapeutic options.
Method: Since 1997 we treated 15 patients with conjunctival melanoma with adjuvant Strontium90 brachytherapy. The mean age was 57 years (25-74y). Most of the patients were males (n=12). The mean follow up was 35 months (1260m). All patients had an involvement of the bulbar conjunctiva, seven patients had additional an involvement of the cornea. All patients received an excisional biopsy of the tumour. Following histological diagnosis the patients received an adjuvant Strontium90 brachytherapy. The treatment was fractionated by 9 irradiations with 6 Gy each. The total dose was 54 Gy.
Results: Seven patients (46%) had no recurrence in the follow up. Three patients (20%) had a recurrence in the treated or adjacent area. Eight patients (53%) developed new tumours in non-treated areas.
Conclusions: Strontium90 brachytherapy is a useful adjuvant in the treatment of conjunctival melanomas and he
Zurück | Back